Brokerages Anticipate Zoetis Inc. (ZTS) Will Announce Quarterly Sales of $1.33 Billion
Equities analysts expect Zoetis Inc. (NYSE:ZTS) to report $1.33 billion in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Zoetis’ earnings, with estimates ranging from $1.31 billion to $1.33 billion. Zoetis posted sales of $1.24 billion during the same quarter last year, which suggests a positive year over year growth rate of 7.3%. The firm is scheduled to report its next quarterly earnings report on Wednesday, November 1st.
According to Zacks, analysts expect that Zoetis will report full-year sales of $1.33 billion for the current fiscal year, with estimates ranging from $5.17 billion to $5.25 billion. For the next financial year, analysts expect that the business will post sales of $5.54 billion per share, with estimates ranging from $5.46 billion to $5.57 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Zoetis.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, hitting the consensus estimate of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter in the prior year, the firm earned $0.49 EPS. The company’s revenue for the quarter was up 5.0% on a year-over-year basis.
A number of analysts recently commented on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $75.00 price objective on shares of Zoetis in a report on Wednesday, September 6th. Stifel Nicolaus reissued a “buy” rating and set a $65.00 price objective on shares of Zoetis in a report on Friday, September 1st. Piper Jaffray Companies set a $73.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research report on Friday, August 25th. Cowen and Company set a $70.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research report on Thursday, August 24th. Finally, Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $62.00 target price on shares of Zoetis in a research report on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the company. Zoetis has an average rating of “Buy” and a consensus price target of $65.44.
Several large investors have recently bought and sold shares of ZTS. CGOV Asset Management raised its position in shares of Zoetis by 2.7% in the first quarter. CGOV Asset Management now owns 169,605 shares of the company’s stock valued at $12,059,000 after buying an additional 4,405 shares during the last quarter. Commerzbank Aktiengesellschaft FI raised its position in shares of Zoetis by 14.1% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 9,287 shares of the company’s stock valued at $496,000 after buying an additional 1,146 shares during the last quarter. Princeton Alpha Management LP acquired a new position in shares of Zoetis in the first quarter valued at approximately $256,000. Suntrust Banks Inc. raised its position in shares of Zoetis by 35.7% in the first quarter. Suntrust Banks Inc. now owns 70,704 shares of the company’s stock valued at $3,772,000 after buying an additional 18,589 shares during the last quarter. Finally, BNP Paribas Arbitrage SA raised its position in shares of Zoetis by 488.3% in the first quarter. BNP Paribas Arbitrage SA now owns 312,638 shares of the company’s stock valued at $16,685,000 after buying an additional 259,492 shares during the last quarter. 93.31% of the stock is owned by institutional investors and hedge funds.
Zoetis (ZTS) opened at 64.70 on Monday. The company’s 50 day moving average is $61.87 and its 200 day moving average is $58.97. The firm has a market cap of $31.65 billion, a P/E ratio of 36.57 and a beta of 1.02. Zoetis has a 52-week low of $46.86 and a 52-week high of $65.12.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.